RIDR-PI-103

RIDR-PI-103

• CAS Number: 2581114-71-6
• UNSPSC Description: RIDR-PI-103 is a reactive oxygen species (ROS)-induced agent release proagent with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation[1][2].
• Target Antigen: Reactive Oxygen Species
• Type: Reference compound
• Related Pathways: Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/ridr-pi-103.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(CN)NC1=CC(N)=CC=C1OC2=CC=CC(C3=NC4=C(C(N5CCOCC5)=N3)OC6=NC=CC=C64)=C2
• Molecular Weight: 511.53
• References & Citations: [1]Mishra R, et al. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. Int J Mol Sci. 2021;22(4):2088. Published 2021 Feb 19. |[2]Rosalin Mishra, et al. Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-10-04.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported